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The choice of adjuvant hormonal therapy in postmenopausal women with hormone receptor positive breast cancer has remained
a matter of controversy and debate. The variety of agents is available, with each claiming to be superior. This clinical survey was
undertaken to get an impression of the physician’s first choice of therapy in an attempt to find out what questions still need to be
answered in the making of “standard of care.” A web-based clinical survey was sent to the cancer physicians around the world, and
182 physicians responded to the survey. Most were medical oncologists in a tertiary care hospital. 36.3% preferred Anastrozole,
35.2% Tamoxifen, and 22.2% Letrozole as their first choice. Data support (67.8%) and safety concerns (30%) were given as the
main reasons for the choice, 63.7% switched their therapy, and 24% had to switch because of side eﬀects. 73.6% used 5 years of
adjuvant hormonal therapy, 6.6% for 7 years, and 4.4% for 10 years. 61.5% follow their patients 3 times monthly, and 73.2% used
laboratory and radiological assessment at each followup.Conclusion. Physicians show disagreement over the choice and duration of
hormonal therapy in this patient population. Clinical trials leading to firm recommendations to set standards from which patients
benefit the most are needed.
1. Introduction
Breast cancer remains the leading cause of cancer related
morbidity and mortality in women, worldwide. Every tenth
new cancer diagnosed is that of breast, and nearly a quarter
of cancers in the women are breast cancer. About 1.4 million
new breast cancer cases are diagnosed every year, and the
burden is going to rise tremendously [1].
The incidence of breast cancer rises with increasing age,
about 80% of breast cancer occur in women above 50 years
of age and nearly half in the age group range of 50 to
69 [2]. The majority of this postmenopausal women with
early breast cancer are hormone, that is, Estrogen (ER) and
progesterone (PR) receptor positive, thus hormonal therapy
is the mainstay of the treatment for them. Hormone therapy,
which essentially deprives the tumor cells of hormone, relies
on the fact that the tumor cells from the breast retain the
property of thriving in the presence of female sex hormones,
and dispossession of which results in inhibition of cancer cell
regrowth.
Hormonal therapy is confirmed to render at least
a benefit of 47% risk reduction for recurrence and that
of 26% for mortality. This benefit alone surpasses the
combined gain obtained by all other interventions in the
adjuvant setting [3]. Most noticeably, the hormonal therapy
intervention benefits all the patients who are hormone
positive, regardless of their tumor size and nodal status.
Tamoxifen has traditionally been considered the gold
standard for adjuvant hormonal therapy in hormone recep-
tor positive breast cancer. The newer third generation
aromatase inhibitors have challenged this unparalleled status
of tamoxifen in postmenopausal women, in whom cessa-
tion of ovarian function leaves only peripheral conversion
of steroids as the source of production of estrogen and
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therefore making it an attractive target to block. Data from
randomized phase III trials has now shown for most available
AIs to have better toxicity profile and at least equal, if not
superior, eﬃcacy than the traditionally used tamoxifen. The
physicians who still prefer to use Tamoxifen quote unique
mechanism of action with possible intrinsic benefits and low
cost as the reason behind the choice [4]. While the advocates
of the newer third generations AI cite greater safety and
improved PFS including a possible overall survival benefit as
strong reasons for shifting the gear in favor of AIs as initial
therapy. There is now in addition a data to support the switch
strategy, in which one agent is alternated with the other, to
have actually more beneficial eﬀects than traditionally used
continuous single agent for five years [5].
This mix of emerging and existing data has under-
standably expanded the options for physician prescription;
besides, the many unanswered or half answered questions
regarding whether to use AIs, which AI, longer use and
switching between AIs and Tamoxifen, has left the treating
physician to use the best personal judgment in making a
choice before solid clinical data are available [6]. With this
backgroundwe conducted a survey to on practicing oncology
physicians worldwide as to see the trends of prescriptions
of hormonal treatment for postmenopausal women in early
adjuvant setting. With the propose of identifying what
questions still need to be answered unequivocally from
clinical trials that would set the standards from which this,
the majority, of breast cancer patients would benefit the
most.
2. Materials and Methods
A web page was developed, which asked physicians five
main questions, after collecting data on their profile and
country of practice. The questions asked about the choice
of physicians hormonal agent in early adjuvant setting for
the postmenopausal women without having a significant co-
morbid, such as a history of osteoporosis, stroke, ischemic
heart disease, and hyperlipidemia. The questionnaire also
asked duration of use of hormonal therapy, “switching
therapy,” laboratory investigations done on followup, and
the frequency of follow up. The main questions were
followed by subsections onwhy a particular choice wasmade.
The webpage address was sent to contactable physicians
whose emails were available in the oncology conference
database. Institutional ethics committee permission was
obtained. SPSS software was used to analyze and prepare the
descriptive data.
3. Results
The survey was sent out to 522 physicians, a total of
182 physicians responded to the questionnaire, and the
response percentage is 34.8%. Most of participants that are
142 (78.0%) were medical oncologists, 24 (13.2%) clinical
oncologists, while 14 (7.8%) were radiation oncologists by
profession. Seventy-five percent of those were males, and
25%were females. Approximately one-third (38.5%) of them
Table 1: Country of practice of physician.
Country of practice no. %
Pakistan 24 13.2
India 24 13.2
Turkey 18 9.9
Egypt 16 8.8
Saudi Arabia 8 4.4
Iran 8 4.4
UAE 6 3.3
UK 6 3.3
USA 6 3.3
Kuwait 6 3.3
France 6 3.3
Lebanon 4 2.2
Morocco 4 2.2
Italy 4 2.2
South Africa 2 1.1
Switzerland 2 1.1
Thailand 2 1.1
Algeria 2 1.1
Argentina 2 1.1
Brunei 2 1.1
Germany 2 1.1
Iraq 2 1.1
no. information 26 14.3
were above 45 years of age while remaining participants were
younger than 45; likewise one-third (33%) of them were in
clinical practice for less than 5 years while remaining two-
thirds have clinical experience of more than 5 years. Most
of the responding physicians were working either as private
physicians or in teaching hospitals (40.7% each). Participants
were frommost parts of the world, including Pakistan, India,
Saudi Arabia, Middle east, UK, Europe, and USA. A detailed
list of the participants is given in Table 1.
In response to question “What is your first choice of
hormonal agent in early adjuvant setting for receptor positive
postmenopausal breast cancer patients, without significant
comorbid like osteoporosis, DVT, heart disease?” 36.3% chose
Anastrozole as their choice of therapy, 35.2% favored
tamoxifen, and 22% preferred Letrozole as their first choice.
The choice of therapy by physicians is depicted in Figure 1.
More than two-thirds (67%) of the participants gave the
reason of having a robust clinical data behind their choice
of therapy, while one-third stated concerns regarding safety
as their primary motivation behind the choice of the agent
of their preference. 31% physicians stated they consider
cost, and 34% consider ease of availability as an additional
factor in making a choice for the hormonal agents. About
8% stated that a trustworthy pharmaceutical company was
the major factor behind the decision regarding the drug
of their choice. Figure 2 summarizes the reason considered
for prescription by diﬀerent physicians. In answer to the
question “Do you switch your patient from one agent to
other during treatment, in a patient who does not have any
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Figure 1: The choice of hormonal agent.
progression of disease?” 63.7% responding physicians said yes
while 33% replied in negative. Amongst the physicians who
switched to another agent 67.2% based their decisions on
presence of data, and 24% had to switch the therapy due to
problems encountered during the patient management. Of
33% of physicians who do not switch their patients from
one agent to other 80% of them based their decisions on
lack of data favoring the benefit of switching the therapy
according to them. Medical oncologists switched therapy
more often than a clinical or radiation oncologists (0.002).
When the participants were asked about the number of
investigation do they undertake before starting the treatment
of the patients in early adjuvant breast cancer treatment for
postmenopausal women, without a major known comorbidity,
73.6% replied that they do some investigations. Table 2
summarizes the laboratory and radiological investigations
frequently requested by the physicians on followup. Nearly
two-thirds of physicians (61.5%) followed their patients 3–
6 monthly during the 1st year of followup while 21% follow
them every other month, 10% every month, and 2% follow
their patients every 6 monthly. Most of physicians (73.6%)
keep their patients for 5 years on chosen hormonal therapy;
8.8% want their patients to take hormonal therapy for 2
years, 6.6% for 7 years, and 4.4% for 10 years. Insignificant
diﬀerences were also noticed based on designation, type,
country, age, and years of practice.
4. Discussion
The concept of breast cancer’s hormone sensitivity is more
than a century old, when oophorectomies were shown to
result in regression of advanced breast cancers [7]. Deriving
benefits from the same concept, subsequent pharmacologic
developments, and refining breast cancer subtypes, today
hormonal therapies are the mainstay of hormone receptor
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Figure 2: Consideration for prescription.
positive breast cancers, which make up about 75% to 80% of
the breast cancer population [8]. The data looking at eﬀects
of chemotherapy and hormonal therapy for early breast
cancer on recurrence and 15-year survival by evaluation of
all randomized trials from early breast cancer trialists group
(EBCTG) suggest a 40% reduction in the risk of recurrence
and 30% reduction in the risk of death with intervention
from hormonal therapy, in women with hormone positive
breast cancer, making hormone therapy, the single most
powerful intervention, in terms of patient benefit [9].
Tamoxifen an oral nonsteroidal, antiestrogenic com-
pound with an intrinsic proestrogenic activity was first
discovered in 1966 and first approved for clinical use in
1977 for metastatic breast cancer. Tamoxifen has been one
of the most commonly prescribed antineoplastic agents of
all times [10]. Tamoxifen was found, through series of
studies, to render suﬃcient therapeutic benefits without
significant toxicity to justify the title of being gold standard
for antiestrogen treatment in breast cancer [11]. The status
of Tamoxifen as a gold standard has been significantly
challenged by the newer generation of Aromatize inhibitors
which in themselves are a robust group of antiestrogenic
therapy [12]. The mechanism of action of AIs relies on
the fact that most estrogen in the postmenopausal women
comes from conversion of steroid hormones to estrogen.
The conversion takes place primarily in the adrenals and
at multiple other sites and is mediated by the aromatase
enzyme. This enzyme is eﬀectively blocked by the third-
generation aromatase inhibitors.
The third-generation aromatase inhibitors first made
their impact when they were compared to megestrol acetate
in metastatic breast cancer (MBC) setting and showed
superior time to progression (TTP) [13]. To date in at
least five randomized Phase III studies done subsequently
AIs demonstrated mostly superior response rate and time
to progression compared to Tamoxifen, when used in
metastatic breast cancer [14, 15].
AIs have been clinically tested in adjuvant setting where
they have unequivocally proved, in at least four phase III
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Table 2: Laboratory tests requested on followup.
Lab test Yes number (%) No number (%)
CBC 134 (73.6) 48 (26.4)
LFT 88 (48.4) 94 (51.6)
Ca++ + Vitamin D level 58 (31.9) 124 (68.1)
Thyroid functions 16 (8.8) 166 (91.2)
Echocardiogram 40 (22.0) 142 (78.0)
Doppler of lower legs 16 (8.8) 166 (91.2)
CA 15-3 54 (29.7) 128 (70.3)
BMD 124 (68.1) 58 (31.9)
Ultrasound pelvis 50 (27.5) 132 (72.5)
trials; that early adjuvant therapy with third-generation aro-
matase inhibitor in postmenopausal women with hormone
positive breast cancer provides better disease-free survival
(DFS) compared to the traditionally used Tamoxifen. All
three available AIs Anastrozole, Letrozole, and Exemestane
have been separately compared with Tamoxifen [16]. The
intergroup Exemestane study studied switching to Exemes-
tane after initial 2-3 years of Tamoxifen therapy in more
than 4500 patients and showed improved disease free and
a modest improvement in overall survival in ER positive
women [17]. The followup study results of long-term use
Letrozole versus placebo after 5 years of tamoxifen in the
NCIC CTG MA.17 trial analysis were recently published and
suggest that extended adjuvant Letrozole was superior to
placebo in DFS and OS [18]. There are, however, serious
considerations associated with the use of AIs in the form of
increased expense and adverse impact on quality of life with
increased bone loss and joint pains [19]. There have, thus,
been calls for careful interpretation of complex scientific data
available and to identify important subsets of population
who are to actually derive the greatest benefit from the use
of AIs [19, 20].
The existing and evolving knowledge and research on
refinement in hormonal therapy for postmenopausal women
generally is favoring the use of AIs, a longer duration of ther-
apy and possibly for using the agents alternatively. However,
the existing data appears not to have reached a threshold
of generating distinct guidelines in favor of their use in this
particular patient population, except for suggestions for the
same, neither has been the duration of therapy, and the
“switch strategy” reached a point where recommendation
can be made unequivocally [21]. Controversies in setting up
the end points, complexity of the data and crossover of the
patients from one arm to the other are some of the factors
responsible for the ambiguity [19].
Our survey clearly demonstrates the discord that is seen
in general amongst the treating physicians. Although our
survey has limitations in the form of number of participants
and geographical variance to claim global representation;
we, nevertheless, find that Tamoxifen is still prescribed
as frequently in postmenopausal women with early stage
breast cancer in adjuvant setting as are AIs. It seems that
physicians favor Anastrozole over Letrozole, without obvious
reason. The steroidal AI Exemestane is prescribed in the
least of AIs. Switch therapy has been found to be suﬃciently
practiced amongst our survey population where close to
64% physicians actually do mention to switch the patients
to Exemestane based on the data. Most physicians did
not continue the therapy for more than 5 years. There
were individual diﬀerences in the frequency of followups
and laboratory or radiological investigations requested by
physicians. It seems that in general there is a lack of
clear guidelines available to physicians on how to follow
the patients after they are over with the active adjuvant
treatments that involve chemotherapy and radiation therapy.
5. Conclusions
Physicians vary over choices on the preferred agents of
hormonal therapy in postmenopausal women in whom
there are no significant comorbid. They also diﬀer quite
significantly among the duration, switching the therapy,
frequency of followup, and necessary laboratory and radio-
logical investigations in such setting. In order to benefit the
patients the most from what is believed to be corner stone
of the therapy, further optimization of hormonal therapy
with answers from clinical trials designed to identify the
subgroups, benefitting the most from a specific hormonal
therapy, shall perhaps set the standards.
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